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Abstract
Background: Connective tissue growth factor (CTGF) is a potent profibrotic factor, which is
implicated in fibroblast proliferation, angiogenesis and extracellular matrix (ECM) synthesis. It is a
downstream mediator of some of the effects of transforming growth factor β (TGFβ) and is
potentially induced by hyperglycemia in human renal mesangial cells. However, whether high
glucose could induce the CTGF expression in vascular smooth muscle cells (VSMCs) remains
unknown. Therefore, this study was designed to test whether high glucose could regulate CTGF
expression in human VSMC. The effect of modulating CTGF expression on VSMC proliferation and
migration was further investigated.
Results: Expression of CTGF mRNA was up-regulated as early as 6 hours in cultured human
VSMCs after exposed to high glucose condition, followed by ECM components (collagen type I and
fibronectin) accumulation. The upregulation of CTGF mRNA appears to be TGFβ-dependent since
anti-TGFβ antibody blocks the effect of high glucose on CTGF gene expression. A small
interference RNA (siRNA) targeting CTGF mRNA (CTGF-siRNA) effectively suppressed CTGF
up-regulation stimulated by high glucose up to 79% inhibition. As a consequence of decreased
expression of CTGF gene, the deposition of ECM proteins in the VSMC was also declined.
Moreover, CTGF-siRNA expressing vector partially inhibited the high glucose-induced VSMC
proliferation and migration.
Conclusion:  Our data suggest that in the development of macrovascular complications in
diabetes, CTGF might be an important factor involved in the patho-physiological responses to high
glucose in human VSMCs. In addition, the modulatory effects of CTGF-siRNA during this process
suggest that specific targeting CTGF by RNA interference could be useful in preventing intimal
hyperplasia in diabetic macrovascular complications.
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Background
Diabetes is a major risk factor for the development of car-
diovascular disease and could promote cardiovascular dis-
eases via multiple mechanisms [1]. Hyperglycemia,
hyperinsulinemia, and dyslipidemia could increase
inflammation and proliferation in the atherosclerotic
lesions in coronary and cerebral arteries [1,2]. Evidence
suggests that high glucose, via various mechanisms, such
as increased production of advanced glycation end prod-
ucts, augmented activation of protein kinase C and
enhanced generation of reactive oxygen species (ROS),
plays a critical role in the development and progression of
diabetic cardiovascular complications [2-4]. In addition,
elevated glucose concentration is also known to activate a
variety of cells to stimulate extracellular matrix (ECM)
synthesis [5-7], which is thought to be mediated by induc-
ing transforming growth factor-β (TGFβ)[8,9] and its
downstream mediator connective tissue growth factor
(CTGF) [10-12]. However, the mechanism why athero-
sclerosis is accelerated in diabetes is still largely unclear.
Recently, CTGF has emerged as a key factor in vascular
remodeling and in the development and progression of
atherosclerosis [13,14]. The CTGF gene contains a TGFβ
response element in its promoter region and it is thought
to be a downstream mediator of the profibrotic effect of
TGF-β [10,15]. But CTGF expression is also regulated by
cAMP [16], high glucose [11,17], endothelin-1[18] and
angiotensin II [18]. High glucose has been known to stim-
ulate CTGF expression in different cell types, including
renal mesangial cells and fibroblasts [10,11,17]. However,
there are few data about the direct effects of high glucose
on ECM protein synthesis and CTGF induction in vascular
smooth muscle cells (VSMC). And the connection
between high glucose and CTGF expression in VSMC
remains unclear. In the view of the increased expression of
CTGF in the atherosclerosis, we hypothesized that CTGF
might be upregulated by high glucose in VSMCs, and the
upregulation of CTGF might contribute to changes of
ECM components. In order to test our hypothesis, we
examined the influence of high glucose on the CTGF
expression in human VSMCs. In previous study, Primary
human umbilical vein smooth muscle cells (HUVSMC)
have been characterized as a model for investigation of
VSMC functions [19]. Therefore, HUVSMCs were used as
a model to study the effects of high glucose on the expres-
sion of CTGF and other ECM genes by RNA interference
and neutralization antibody in this paper. Our data dem-
onstrate that high-glucose-stimulated VSMC growth and
migration, as well as the high-glucose-induced ECM com-
ponents deposition in VSMCs were attenuated by CTGF
inhibition, which suggested that therapies targeting CTGF
might be useful in preventing intimal hyperplasia in the
atherosclerotic lesions in diabetic macrovascular compli-
cations.
Results
Effect of high glucose on CTGF expression in HUVSMCs
To determine whether high glucose modulates the expres-
sion of CTGF mRNA, HUVSMCs were treated with 25
mmol/L D-glucose, and total RNA was isolated at various
times from 6 to 48 hours. Real-time quantitative RT-PCR
revealed that high glucose rapidly induced the expression
of CTGF above basal levels 6 hours after treatment. The
induction of CTGF expression was peaked at 12 hours
after treatment, and then declined to near baseline by 24
hours (Figure 1a). To exclude the possibility that high-glu-
cose-induced CTGF expression was caused by increased
osmolarity, we tested the effect of 25 mmol/L mannitol
on CTGF mRNA expression. Compared with cells in the
normal glucose medium, there was no significant stimu-
latory effect on CTGF expression in HUVSMC cells incu-
bated for 24 hours in normal glucose media containing 25
mmol/L mannitol, confirming the specificity of the high
glucose response in stimulating the CTGF expression in
HUVSMCs (Figure 1a).
Under serum-starvation condition, growth-arrested
HUVSMCs expressed low level of CTGF protein, as shown
by Western blot as a band of ≈38 Kda. Total cellular CTGF
protein levels began to increase after treated with high glu-
cose for 12 hours, and peaked at 24 hours post-treatment.
The elevated CTGF level lasted up to 48 hours after treat-
ment (Figure 1b). The expression of CTGF protein was
also analyzed by immunocytochemistry, which showed
that growth-arrested HUVSMCs presented a slight CTGF
staining, and treatment with high glucose for 24 hours sig-
nificantly increased cytoplasmic CTGF staining (Figure
1c). These data suggest that high glucose induces both
CTGF mRNA and protein production in HUVSMCs.
TGF-β has been identified as a potent inducer of CTGF
expression and it is also a very important regulator of ECM
in different cell types [20,21]. Our results showed that
TGF-β treatment (10 ng/mL) also induced CTGF expres-
sion in the HUVSMCs. Induction of CTGF by high glucose
may occur indirectly, mediated by the action of TGF-β. To
test this hypothesis, we examined the effect of a neutrali-
zation antibody of TGF-β (10 μg/mL, R&D Systems, USA)
on high glucose-induced CTGF expression. We observed
that the blockade of TGF-β by a neutralization antibody
against active TGF-β partly decreased high glucose-
induced CTGF gene and protein production (Figure 2a
and 2b). This partial inhibition suggests that endogenous
TGF-β synthesis is, at least partly, involved in high glu-
cose-induced CTGF production.
Role of CTGF in high glucose-induced ECM accumulation 
in HUVSMCs
Previous studies have showed that high glucose increased
ECM accumulation in cultured smooth muscle cellsBMC Cell Biology 2007, 8:1 http://www.biomedcentral.com/1471-2121/8/1
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High glucose increases CTGF mRNA expression (a) and protein production (b, c) in cultured HUVSMCs Figure 1
High glucose increases CTGF mRNA expression (a) and protein production (b, c) in cultured HUVSMCs. 
Growth-arrested HUVSMCs were stimulated with high glucose (HG, 25 mmol/L) for different durations. (a) Quantitative RT-
PCR (Q-PCR) results. Total cellular RNA was isolated from normal glucose (NG, 5.5 mmol/L), high glucose (HG) or mannitol 
(25 mmol/L) treated HUVSMCs. After reverse transcription, they were subjected to quantitative PCR (Taqman) analysis to 
determine CTGF mRNA level. Graph is representative of relative CTGF levels in the various conditions. Experiments were 
performed five times with the similar results (n = 5 in each group). * P < 0.05 vs NG. (b) Representative Western blot (top) 
and values of total CTGF production (means ± SEM of 3 experiments, bottom). Results of total CTGF protein production 
were obtained from densitometric analysis and expressed as ratio of CTGF/β-actin. * P < 0.05 vs NG. (c) Immunocytochemical 
staining of CTGF protein expression in HUVSMCs (top, magnificent of 400×) and integrated optical density (IOD) of the CTGF 
staining was measured on the images using the Image-Pro Plus software (bottom). Figure shows a representative experiment 
out of 3 performed experiments. * P < 0.05 vs scrambled-siRNA transfection under normal glucose media condition. # P < 0.05 
vs scrambled-siRNA transfection under high glucose media condition. NG: normal glucose; HG: High glucose; scrambled siRNA: 
scrambled-siRNA plasmid transfection; siRNA: siRNA-CTGF plasmid transfection.BMC Cell Biology 2007, 8:1 http://www.biomedcentral.com/1471-2121/8/1
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[9,22]. We therefore investigated whether CTGF was
involved in high glucose-induced ECM components dep-
osition, including collagen type I and FN in HUVSMCs.
Consistent with other reports [9,22], we observed that
ECM components (collagen type I and FN) accumulated
significantly under high glucose condition using both
real-time PCR and immunocytochemistry analysis (Figure
3).
To block CTGF actions, we used a CTGF-specific small
inhibitory RNA construct (CTGF-siRNA) to knockdown
CTGF expression. CTGF-siRNA significantly inhibited
basal and high glucose-induced CTGF gene expression in
HUVSMC as evaluated by quantitative PCR. Similarly,
CTGF-siRNA knockdown of CTGF protein was confirmed
by Western blot and immunocytochemistry (Figure 3 and
1c). The knockdown of CTGF significantly reduced mRNA
and protein levels of collagen type I and FN (Figure 3). As
a negative control, the scrambled siRNA had no effect on
any of CTGF, collagen type I or FN expression in HUVS-
MCs (Figure 3a). Thus, the data demonstrate that CTGF is
a downstream mediator of high glucose-induced ECM
components accumulation in HUVSMCs.
Role of CTGF in the high glucose-induced proliferation of 
HUVSMCs
To examine a role of CTGF in high glucose-induced prolif-
eration, we grew quiescent, CTGF gene-silenced HUVSMC
cells under high glucose or normal glucose conditions for
48 hours. [3H]-thymidine incorporation and cell counting
were quantitated in these cells.
Figure 4 shows that HUVSMC cells exposed to high glu-
cose conditions was induced a significant 69% increase in
[3H]-thymidine incorporation compared with normal
glucose conditions; and 58% increase in cell number. Our
results are consistent with other reports [23,24], which
showing that high glucose conditions stimulate the prolif-
eration of cultured VSMCs. To evaluate the contribution
of increased medium osmolarity to DNA synthesis, we
also examined the effect of 25 mmol/L mannitol on [3H]-
thymidine incorporation. The [3H]-thymidine incorpora-
tion in cells incubated 48 hours in normal glucose
medium containing 25 mmol/L mannitol was not signif-
icantly different from that in the normal glucose medium.
This result ruled out the possibility that, the high glucose-
induced CTGF up-regulation was caused by increased
High glucose-induced CTGF upregulation in HUVSMC is dependent on TGF-β Figure 2
High glucose-induced CTGF upregulation in HUVSMC is dependent on TGF-β. HUVSMC cells were co-treated 
with high glucose (HG, 25 mmol/L) and a TGF-β neutralizing antibody (Ab; 10 μg/mL) for 24 hours. (a) Q-PCR results: CTGF 
mRNA expression was assayed by Q-PCR. Experiments were performed five times with the similar results (n = 5 in each 
group). * P < 0.05 vs normal glucose (NG). # P < 0.05 vs TGF-β 1. (b) Representative Western blot of 3 performed experi-
ments (top) and values of total CTGF production (mean ± SEM, bottom). * P < 0.05 vs NG. # P < 0.05 vs TGF-β1. NG: normal 
glucose; HG: high glucose; TGF-β1: TGF-β1 treatment (10 ng/mL); Ab-TGF-β1: TGF-β neutralizing antibody treatment.BMC Cell Biology 2007, 8:1 http://www.biomedcentral.com/1471-2121/8/1
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siRNA-CTGF transfection reduces basal and high glucose-induced CTGF, collagen type I and FN mRNA (a) and protein  expression (b, c and d) in HUVSMC Figure 3
siRNA-CTGF transfection reduces basal and high glucose-induced CTGF, collagen type I and FN mRNA (a) 
and protein expression (b, c and d) in HUVSMC. (a) Q-PCR results: Growth-arrested HUVSMCs were transfected with 
scrambled or CTGF-siRNA plasmids for 24 hours and then exposed to normal glucose (NG) or high glucose (HG) conditions 
for 24 to 72 hours. CTGF, collagen type I and FN mRNA expression were assayed by Q-PCR. Experiments were performed 
five times with the similar results (n = 5 in each group). (b) Representative Western blot (top) and values of total CTGF pro-
duction (means ± SEM of 3 experiments, bottom). Results of total CTGF protein production were obtained from densitomet-
ric analysis and expressed as ratio of CTGF/β-actin. (c) Immunocytochemistry staining of collagen type I protein expression in 
HUVSMCs (top, magnificent of 400×) and integrated optical density (IOD) of the collagen type I staining was measured on the 
images using the Image-Pro Plus® software (bottom). Figure shows a representative experiment of 3 performed. (d) Immuno-
cytochemistry staining of fibronectin (FN) protein expression in HUVSMCs (top, magnificent of 400×) and integrated optical 
density (IOD) of the fibronectin staining was measured on the images using the Image-Pro Plus® software (bottom). Figure 
shows a representative experiment of 3 performed. * P < 0.05 vs scrambled siRNA transfection under normal glucose (NG) 
media condition. # P < 0.05 vs scrambled siRNA transfection under high glucose (HG) media condition. Scrambled siRNA: scram-
bled siRNA plasmid transfection; siRNA: siRNA-CTGF plasmid transfection; NG: normal glucose; HG: High glucose.BMC Cell Biology 2007, 8:1 http://www.biomedcentral.com/1471-2121/8/1
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osmolarity (data not shown). Transfection of CTGF-
siRNA in HUVSMC partly prevented the increase in cell
proliferation in high glucose (41% inhibition), and to a
less extent, in normal glucose medium controls (13%
inhibition) (Figure 4). Our data indicate that CTGF is
involved in basal and high glucose-induced HUVSMC
proliferation
Role of CTGF in high glucose-induced migration in 
HUVSMCs
Monolayer scratch wound assays have been used by oth-
ers to study migration of VSMCs [25,26]. In order to exclu-
sively measure migration, DNA synthesis of HUVSMCs
was further blocked by addition of hydroxyurea. Our
results showed that 6 hours after injury, the CTGF-siRNA
transfected cells were less than the mock transfection or
the scrambled-siRNA treated cells to migrate into the
wound gap (Figure 5). Furthermore, the expression of
matrix metalloproteinase-2 (MMP-2) mRNA and protein
were also reduced in the CTGF-siRNA transfected cells.
MMP-2 is an important factor directly involved in control-
ling cell movement and the turnover of ECM [27]. In com-
parison, the scramble-siRNA transfected cells showed
unchanged MMP-2 mRNA expression (Figure 6).
Discussion
In the present study, the potential correlation between
high glucose and CTGF was investigated in cultured
HUVSMCs. The major finding of this study is that high
glucose up-regulates the expression of CTGF in HUVSMCs
and knockdown of CTGF gene results in the inhibition of
high glucose-induced VSMC proliferation and migration.
These observations establish acritical role of CTGF in
mediating high-glucose induced ECM accumulation in
VSMC and suggest that inhibition of CTGF may be useful
for preventing abnormal VSMC growth and migration in
diabetic vessels.
CTGF was first identified as a 38-kDa cysteine-rich pro-
tein, which can be specifically induced by TGF-β. It is
recently found that CTGF is expressed abundantly in
atherosclerotic blood vessels, but only marginally in nor-
mal vascular tissues. CTGF is one of the key factors
involved in the development of atherosclerotic lesions
[13]. To further assess the role of CTGF in diabetic cardio-
CTGF is involved in high glucose-induced proliferation of cultured HUVSMCs Figure 4
CTGF is involved in high glucose-induced proliferation of cultured HUVSMCs. Quiescent cells were transfected 
with scrambled or CTGF-siRNA expression plasmids for 24 hours and then exposed to HG for 48 hours followed by the 
assessment of [3H]-thymidine incorporation (a) and cell number counting (b). Each value is the mean ± SEM of 6 separate 
experiments. * P < 0.05 vs scrambled siRNA transfection under normal glucose (NG) condition. # P < 0.05 vs scrambled siRNA 
transfection under high glucose (HG) condition. Scrambled siRNA: scrambled siRNA plasmid transfection; siRNA: CTGF-siRNA plas-
mid transfection.BMC Cell Biology 2007, 8:1 http://www.biomedcentral.com/1471-2121/8/1
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Role of CTGF in high glucose-induced migration of cultured HUVSMCs Figure 5
Role of CTGF in high glucose-induced migration of cultured HUVSMCs. Quiescent cells were transfected with 
scrambled or CTGF-siRNA expressing plasmid for 24 hours, then exposed to HG for 48 hours, and followed by the measure-
ment of cell migration in a monolayer scratch wound assay. Figure (a) shows a representative result of three mock trans-
fected experiments (Magnification 200×). Figure (b) shows a representative result of three scrambled siRNA plasmid 
transfected experiments (Magnification 200×). Figure (c) shows a representative result of three CTGF-siRNA plasmid trans-
fected experiments (Magnification 200×). Figure (d) shows the average of migrated cells in three experiments. * P < 0.05 vs 
mock transfection or scrambled siRNA transfection.BMC Cell Biology 2007, 8:1 http://www.biomedcentral.com/1471-2121/8/1
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vascular complications, we examined whether CTGF was
regulated by high glucose in VSMC. Our data show that
exposure of HUVSMC to high glucose, but not iso-
osmotic mannitol, leads to an increase of CTGF expres-
sion, and the induction of CTGF by high glucose is partly
mediated via TGF-β pathway.
Some studies have showed that high glucose may mediate
diabetic renal and macrovascular complications by stimu-
lating ECM production [9], and the increased ECM syn-
thesis accounts mainly for intimal plaque formation in
the atherosclerotic lesions in diabetic vessels, so the effect
of blocking CTGF action on ECM expression was further
examined in this study. By CTGF-specific siRNA, our
results demonstrate that knockdown of CTGF expression
prevents ECM production in VSMC, indicating that CTGF
plays an important role in mediating ECM accumulation
in VSMC in response to high glucose.
In addition to increased ECM deposition in VSMC, it has
been recognized that VSMC proliferation within the vessel
wall is another critical pathogenic feature in the develop-
ment of atherosclerosis. Glucose metabolism has been
implicated to play an important role in this cellular mech-
anism [1]. Neointimal formation, the leading cause of res-
tenosis, is also caused by proliferation of VSMCs. Patients
with diabetes mellitus have higher restenosis rates after
coronary angioplasty than non-diabetic patients.
Enhanced proliferation of VSMC has also been demon-
strated in diabetic experimental animal models [24]. In
addition, cultured VSMC cells grown in media with high
glucose concentration (to mimic hyperglycemia of diabe-
tes) have exhibited increased cell proliferation [23,24]
Several intracellular signals elicited by high glucose are
responsible for VSMC cell proliferation, including
increased expression of TGF-β receptor type II via PKC-β
[28], enhanced intracellular ROS production [29], and
siRNA-CTGF transfection reduces basal and high glucose-induced MMP-2 mRNA (a) and protein expression (b) in HUVSMC Figure 6
siRNA-CTGF transfection reduces basal and high glucose-induced MMP-2 mRNA (a) and protein expression 
(b) in HUVSMC. (a) Q-PCR (Taqman) results: Growth-arrested HUVSMCs were transfected with siRNA-CTGF plasmid for 
24 hours and then exposed to normal or high glucose conditions for 24 hours. 1 μg of total RNA was reverse-transcribed into 
cDNA and analyzed for expression of MMP-2 mRNA by real-time PCR. Experiments were performed five times with the simi-
lar results (n = 5 in each group). (b) Representative Western blot (top) and values of total CTGF production (means ± SEM of 
3 experiments, bottom). Results of total MMP-2 protein production were obtained from densitometric analysis and expressed 
as ratio CTGF/β-actin. * P < 0.05 vs scrambled siRNA transfection under normal glucose (NG) condition. # P < 0.05 vs scram-
bled siRNA transfection under high glucose condition (HG). Scrambled siRNA: scrambled siRNA plasmid transfection; siRNA: CTGF-
siRNA plasmid transfection.BMC Cell Biology 2007, 8:1 http://www.biomedcentral.com/1471-2121/8/1
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suppressed apoptosis via upregulation of bcl-xl and bfl-1/
A1 levels through PI-3K and ERK1/2 pathways in VSMCs
[30]. Our results suggest a role of CTGF in the HUVSMCs
proliferation induced by high glucose.
The migration of VSMCs from the media into the
neointima is important in the pathogenesis of atheroscle-
rosis. This process is regulated by multiple factors, and it
involves changes in the interaction between the ECM and
intracellular signaling cascades that regulate cell move-
ment [31,32]. High glucose is one of the multiple factors
that could increase VSMCs migration [29,32]. CTGF over-
expression can significantly increase the activity of MMP-
2 in VSMC conditioned medium and increase the migra-
tion of VSMC [25], which suggests a link between high
glucose-induced VSMC migration and CTGF over-expres-
sion. MMP-2 is able to induce VSMC migration and pro-
liferation in addition to ECM degradation, and it has also
been shown to play an important role in atherosclerotic
plaque formation and restenosis after vessel injury [33].
Consistent with previous report [34], our data demon-
strate that CTGF-siRNA suppresses high glucose-induced
HUVSMC migration via, at least partly, down-regulation
of MMP-2.
Recently, RNA interference (RNAi) has reinvigorated the
therapeutic prospects for inhibiting gene expression and
promised many advantages over binding inhibitors,
including high specificity. RNAi provides a new, reliable
method to investigate gene function and has the potential
for gene therapy. In mammalian cells, 21-or 22-nucle-
otide (nt) RNAs with 2-nt 3' overhangs (small inhibitory
RNAs, siRNA) exhibit a RNAi effect [35]. It is important to
avoid homologous sequences within a target mRNA in a
given protein family [35]. One of the reported CTGF
siRNA sequences targets the coding region 360–380 from
the first nucleotide of the start codon of CTGF mRNA [36],
but it is located within one of the four conserved cysteine
rich modular domains-the von Willebrand factor (vWF)
domain (307–486 bp) in the CTGF mRNA [37]. In order
to construct a specific CTGF-siRNA, we searched for
regions of low homology to other genes of the CCN fam-
ily. With the help of some siRNA-design tools in the Inter-
net, we designed five specific pairs of DNA templates
coding siRNA against human CTGF-mRNA and recon-
structed the plasmid pSilencer3.1-H1 siRNA-CTGF. How-
ever, we only observed one pair of the DNA templates
coding the sequence (nucleotides 762–782) has signifi-
cant effect (79%) to down-regulate the expression of basal
and high glucose-induced CTGF expression in HUVSMCs.
The reason why only one out of five pairs of siRNA shows
specific gene knockdown is unclear. This problem
remains to be one of the many challenges of therapeutic
usage of siRNA [38]. Down regulation of CTGF markedly
reduces the synthesis of high glucose-induced ECM pro-
teins such as collagen type I and fibronectin. Our results
indicate that CTGF is involved in ECM accumulation
under normal glucose condition, but also it is an impor-
tant mediator in the ECM deposition induced by high glu-
cose in VSMC. Antagonism of CTGF function could
possibly attenuate progression of diabetic macrovascular
complications.
Conclusion
CTGF might be involved in high glucose-induced prolifer-
ation, migration and ECM production in VSMC, and
could contribute to the pathogenesis of diabetic macrov-
ascular complications. Our results indicate that RNA
interference is a useful tool to investigate CTGF gene func-
tion and might be useful in developing a potential therapy
for diabetic macrovascular diseases.
Methods
Cell culture
HUVSMCs and smooth muscle cell medium were pur-
chased from Technoclone (Vienna, Austria). In all experi-
ments, confluent HUVSMC cells at passage 4 to 8 were
washed and incubated with serum-free media for 24
hours. These cells were treated with D-glucose at normal
glucose (NG, 5.5 mmol/L) or high glucose (HG, 25
mmol/L, as previously used in other reports [17,23]) lev-
els. At the end of their respective incubation periods, cell
proliferation, migration and CTGF expression were
assessed. Each experiment was repeated at least three
times throughout the study.
Quantitative real-time reverse transcription PCR
The expression of CTGF, collagen type I, fibronectin (FN)
and matrix metalloproteinase-2 (MMP-2) gene was iden-
tified by quantitative RT-PCR. Total RNA extraction and
real-time RT-PCR were performed as previously described
[17,39]. Human-specific CTGF, collagen type I and MMP-
2 primers and probes were designed using Primer Express
Software 1.0(PE Applied Biosystems), synthesized and
HPLC purified (Takara, Dalian, China). Primer sequences
were as follows: CTGF-F:5'-GCCTGTTCCAAGACCTGT-3';
GCTGF-R: 5'-GGATGCACTTTTTGCCCTTCTTA-3'; CTGF
TaqMan probe: 5'-CTCCACCCGGGTTACCAATGAC-3'.
Collagen type I (Col1α1)-F: 5'-TGTCGATGGCTGCAC-
GAGT-3'; Collagen type I (Col1α1)-R: 5'-CAACGTC-
GAAGCCGAATTCCT-3'; Col1α1 TaqMan probe: 5'-
CCCCTTGGACGTTGGTGCCC-3'. MMP-2-F: 5'-CCGT-
GGTGAGATCTTCT-TCT-3': MMP-2-R: 5'-CCTCGTATAC-
CGCATCAATCT-3'; MMP-2 TaqMan: 5'-
CACATTCTGGCCTGAGCTCC-3'. GAPDH-F: 5'-GGGT-
GTGAACCATGAGAACT-3'; GAPDH-R: 5'-CAAAGTTGT-
CATGGATGACCT-3'; GAPDH TaqMan probe: 5'-
CTGCACCAACTGCTTAGC-3'. Human-specific FN prim-
ers and probe were synthesized by using the publishedBMC Cell Biology 2007, 8:1 http://www.biomedcentral.com/1471-2121/8/1
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sequences [40]. For quantification, the target sequence
was normalized to the GAPDH mRNA levels.
Immunocytochemistry
HUVSMC were plated onto coverslips in six-well plates,
growth arrested and treated with D-glucose at 5.5 mmol/
L or 25 mmol/L levels with or without other compounds.
Coverslips were then fixed and blocked as described
before [18], followed by exposed to the primary antibod-
ies (anti-CTGF, anti-collagen type I or anti-FN antibody,
Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA).
The second antibody was peroxidase-conjugated antibody
and the final reaction was visualized with diaminobenzi-
dine (DakoCytomation, Hamburg, Germany), followed
by counterstaining with hematoxylin (Sigma-Aldrich).
Images were collected using an Eclipse TE2000-U micro-
scope system (Nikon, Japan) and analyzed with Image-
Pro Plus® software (Version 4.5, Media Cybernetics, Silver
Spring, USA) to semi-quantitatively determine the expres-
sion of CTGF, collagen type I or FN.
Western Blot analysis
Western-blot analysis of CTGF or MMP-2 was performed
using rabbit polyclonal antibodies against CTGF or MMP-
2 (Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA),
according to the method described before [41,42]. In
brief, HUVSMC cell lysates (40 μg) were separated by
denaturing 10% SDS-PAGE and then transferred to poly-
vinylidene difluoride (PVDF) membrane (Millipore)
using a MiniProtein III system (Bio-Rad, CA, USA). Trans-
ferred proteins were probed with the rabbit polyclonal
anti-CTGF or anti-MMP-2 antibodies (1:250) and visual-
ized using the horseradish peroxidase conjugated second-
ary anti-rabbit (1:3000; Amersham Biosciences) antibody
and ECL solution. Equal protein loading was verified by
reprobing the membrane with an anti β-actin antibody
(Santa Cruz Biotechnology, Inc.). For quantification pur-
poses, densitometric measurements were performed using
Quantity One® image analysis software for Windows (Bio-
Rad). All specific blot values were corrected forβ-actin
expression.
Plasmid construction and transfection
The pSilencer 3.1-H1 neo siRNA expressing plasmid was
purchased from Ambion (Austin, TX, USA). The CTGF-
siRNA plasmid expressing short hairpin small interfering
RNA (siRNA) under the control of the polymerase-III H1-
RNA promoter was produced after inserting pairs of
annealed DNA oligonucleotides between the BamHI and
HindIII restriction sites. The targeted 21-nucleotide (nt)
sequences derived from human CTGF mRNA (Genebank:
NM_001901; bp 762–781 from the first nucleotide of the
start codon) were selected. A scrambled control siRNA
with the same nucleotide composition as CTGF siRNA but
lacking significant sequence homology to the human
genome was also constructed. Transient transfection was
performed by use of the cationic lipid Lipofectamine 2000
(Invitrogen, USA) according to the manufacturer's specifi-
cations. HUVSMCs were transfected with CTGF-siRNA or
scrambled-siRNA expressing plasmids 24 hours before
exposure to high glucose concentration.
Assessment of cell proliferation
[3H]-thymidine incorporation and cell counting were
used in the assessment of cell proliferation, as described
previously [23]. Briefly, HUVSMC cells were subcultured
in six-well plates and incubated with serum-free medium
for 24 hours. Quiescent cells were transfected with CTGF-
siRNA or scrambled siRNA expressing plasmids for 24
hours, then either exposed to normal glucose serum free
media or maintained in high glucose serum free media for
48 hours. [3H]-thymidine (1 mCi/ml, specific activity 20
Ci/mmol) was added to one set of wells in the last 4 hours
of incubation. The other sets of wells were processed for
cell counting. For the assessment of [3H]-thymidine incor-
poration, media was removed at the end of incubation,
and cells were washed with 10% trichloroacetic acid and
digested with 0.5 N NaOH. Radioactivity in the cell digest
was counted in a Beckman scintillation counter. [3H]-thy-
midine incorporation is expressed as the total counts per
minute per well.
Scratch wound migration assay
Cell migration was measured using a monolayer scratch
injury assay, as described previously [25,26]. Briefly,
HUVSMCs were plated at confluence onto glass chamber
slides and then transfected with CTGF-siRNA, or scram-
bled siRNA expressing plasmids for 24 hours. During the
last 4 hours, hydroxyurea was added to a final concentra-
tion of 5 mmol/L to further prevent DNA synthesis. Fol-
lowing transfection, HUVSMCs were cultured under
normal glucose or high glucose serum free media, and a
uniform straight scratch was made in the cell monolayer
using a 200 μL yellow plastic pipet tip. Monolayers were
washed gently, marked (for reference) and photographed
using an inverted microscope (Nikon Eclipse TE2000-Y
system, Japan). After incubation for 48 hours at 37°C, the
cells that have moved into the wound area were quanti-
tated. Four counts were made at various points along each
wound that were photographed initially and marked.
Migrated cell numbers were derived from the average of
these fields in triplicates.
Statistical analysis
The experimental data were expressed as means ± SEM.
Group means were compared by ANOVA using the statis-
tical software program SPSS 10.0 for Windows (Chicago,
IL, USA), and P value < 0.05 was considered statistically
significant in all cases.BMC Cell Biology 2007, 8:1 http://www.biomedcentral.com/1471-2121/8/1
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